Loading...
XNSE
LASA
Market cap5mUSD
Nov 12, Last price  
10.68INR
Name

Lasa Supergenerics Ltd

Chart & Performance

D1W1MN
XNSE:LASA chart
P/E
—
P/S
0.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.23%
Rev. gr., 5y
-3.16%
Revenues
1.42b
+36.53%
01,996,625,0002,435,259,0001,695,730,0001,672,566,0002,023,795,0001,371,267,0001,295,678,0001,043,350,0001,424,481,000
Net income
-148m
L-32.09%
0-6,253,000123,399,000-120,306,00036,284,000227,777,000-53,672,000-386,207,000-217,306,000-147,575,000
CFO
-28m
L
-3,500,000250,200,000402,799,000406,579,000136,224,000413,103,000104,898,000-173,004,00021,387,000-28,237,000
Dividend
Sep 16, 20220.25 INR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.
URL
https://lasalabs.com/
IPO date
Sep 21, 2017
Employees
Domiciled in
IN
Incorporated in
IN

Valuation

Title
INR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT